Exponent, Inc. — Form 10-Q Summary
Period clarification: The supplied filing is for the three months ended March 31, 2023, compared with the three months ended April 1, 2022. This differs from the request metadata identifying 2022 Q1.
Business context and reporting period
Exponent is an engineering and scientific consulting firm. Its two reportable segments are Engineering and Other Scientific, and Environmental and Health. The unaudited results cover the first quarter of fiscal 2023.
Key financial results
| Metric | Q1 2023 | Comparable 2022 period |
|---|---|---|
| Revenue | $140.3 million | $128.5 million |
| Revenue before reimbursements | $128.7 million | $117.9 million |
| Operating income | $29.1 million | $36.7 million |
| Net income | $29.1 million | $29.6 million |
| Diluted earnings per share | $0.56 | $0.56 |
| Net cash used in operating activities | $6.7 million | $6.4 million |
Revenue grew 9.2%; operating income fell 20.7%, while net income decreased 1.6%. Operating margin was approximately 20.8% of revenue, versus 28.6% in the prior-year quarter. EBITDA was $35.8 million, or 27.8% of revenue before reimbursements, compared with $34.5 million, or 29.2%. EBITDAS, a non-GAAP measure, was $42.8 million versus $41.3 million.
Cash and cash equivalents were $125.6 million at March 31, 2023, down from $161.5 million at December 30, 2022. Investing activities used $5.7 million, principally reflecting capital expenditures; financing activities used $23.7 million, including $14.5 million in dividends. The company reported no borrowings or debt balance in the supplied balance sheet. Operating lease liabilities totaled $16.4 million. Current assets were $318.3 million and current liabilities $109.2 million.
Material changes and drivers
- Engineering and Other Scientific revenue rose 11.9% to $117.0 million, driven by higher billable hours and rates; Environmental and Health revenue fell 2.5% to $23.3 million.
- Billable hours increased 3%, but utilization declined to 70% from 77%; technical full-time-equivalent employees increased 12% to 1,052.
- Compensation and related expenses increased 22.4% to $84.2 million, rising to 60.0% of revenue from 53.5%. Higher staffing and deferred-compensation-related expense contributed.
- Corporate operating expense increased to $22.1 million from $9.6 million. Deferred compensation expense and corresponding other income each reflected an $8.6 million year-over-year swing, tied to plan-asset values.
- Other income was $6.4 million, compared with a $3.9 million loss, reflecting deferred compensation investment results and higher interest income. The effective tax rate was 18.0%, versus 9.7%, primarily due to a smaller excess tax benefit from stock-based awards.
Outlook, risks, and contingencies
Management provided no specific numerical revenue or earnings guidance. It expects compensation costs, other operating expenses, and general and administrative expenses to rise as it hires selectively, adjusts compensation, and invests in infrastructure and business development. Management said cash, cash equivalents, short-term investments, and operating cash generation should be sufficient for at least the next 12 months, including working capital, capital expenditures, dividends, and repurchases.
Management cited demand for reactive services, including litigation, product safety, and recall work, and proactive work in consumer products, chemicals, utilities, automotive, and life sciences. Risks include changing economic conditions and demand, engagement timing, competition and pricing, employee attraction and retention, regulatory and tort-reform effects, and claims against the company. The company also has foreign-currency exposure and does not hedge it; management said impacts had not been significant to date, but international growth could increase exposure. No material legal proceedings were reported; ordinary-course claims were not expected to materially affect results, though outcomes remain uncertain. No material changes to previously disclosed risk factors were reported.
A $0.26-per-share dividend was declared after quarter-end, payable June 23, 2023, to holders of record on June 9, 2023. No shares were repurchased during the quarter; $62.6 million remained available under the repurchase programs.
Important facts for investors to verify
- Confirm the reporting period: the filing is Q1 2023, not Q1 2022.
- Assess whether hiring and lower utilization can be converted into billable work without further pressure on operating margins.
- Track the contribution and volatility of deferred-compensation plan assets and related expense/income.
- Monitor operating cash flow, which was negative in the quarter, and the decline in cash after dividends and capital spending.
- Review customer concentration: one client represented 13% of revenue in both comparable quarters.
- Verify future dividend and repurchase decisions against cash needs, investment plans, and management’s stated liquidity outlook.